Page 1

Johnson - Johnson Johnson & Johnson Reports Q3 2021 Results : FOR IMMEDIATE RELEASE • Total sales growth of 10.7 % to $ 23.3 Billion with operational growth of 9.9 % * and adjusted operational growth of 10.6 % * • Earnings per share of $ 1.37 increasing 3.0 % and adjusted earnings per share of $ 2.60 increasing 18.2 % * • Company increasing 2021 Full - Year Guidance New Brunswick , N.J. ( October 19 , 2021 ) - Johnson & Johnson ( NYSE : JNJ ) today announced results for third- quarter 2021. " Our third - quarter results demonstrate solid performance across Johnson & Johnson , driven by robust above - market results in Pharmaceuticals , ongoing recovery in Medical Devices , and strong growth in Consumer Health , " said Alex Gorsky , Chairman and Chief Executive Officer . " In the face of evolving marketplace dynamics resulting from the effects of COVID - 19 and other global trends , we have continued to demonstrate the responsiveness and agility required to meet the needs of our stakeholders , while also successfully investing in a pipeline of innovation and key commercial platforms to drive our future growth . I am incredibly proud of our Company's transformative growth over the last decade . As I prepare to transition the role of CEO to Joaquin Duato in January , I want to extend my deepest gratitude to our colleagues around the globe who work tirelessly to deliver solutions to address the world's most urgent and unmet healthcare challenges . " OVERALL FINANCIAL RESULTS Q3 ( $ in Millions , except EPS ) 2021 2020 % Change Reported Sales $ 23,338 $ 21,082 10.7 % Net Earnings 3,667 3,554 3.2 % EPS ( diluted ) $ 1.37 $ 1.33 3.0 % Q3 Non - GAAP * ( $ in Millions , except EPS ) 2021 2020 % Change Operational Sales 1,2 Adjusted Operational Sales 1,3 9.9 % 10.6 Adjusted Net Earnings " 1.4 Adjusted EPS ( diluted ) 1 1.4 $ 6,968 2.60 $ 5,868 18.7 % 2.20 18.2 % 1 Non - GAAP financial measure ; refer to reconciliations of non - GAAP financial measures included in accompanying schedules 2 Excludes the impact of translational currency 3 Excludes the net impact of acquisitions and divestitures and translational currency 4 Excludes intangible amortization expense and special items